Medical Dept, Solus, A Div. of Ranbaxy, Ranbaxy House, Plot No. 89, Street 15, MIDC, Andheri (W), Mumbai - 400 093.
Indian J Psychiatry. 2004 Apr;46(2):150-5.
Before the 1990s, treatment of psychoses centred on conventional agents whose tolerability was limited by extrapyramidal symptoms (EPS). The past decade has seen the emergence of newer generation of antipsychotic agents. These agents provide better negative symptom efficacy, less impaired cognition and lower risk of extrapyramidal syndromes. Aripiprazole, a new atypical antipsychotic drug, displayed efficacy similar to risperidone and haloperidol in numerous clinical trials. Aripiprazole does not cause significant prolactin elevation and is associated with a low rate of clinically significant weight gain compared with other atypical antipsychotics. Aripiprazole is a study drug for treating schizophrenia and has a novel pharmacologic profile. Aripiprazole provides a new treatment option with limited adverse effects for patients in need of antipsychotic therapy. The present study is a 4-week, open-labelled, randomized postmarketing clinical study conducted using aripiprazole as the study drug. Fixed doses of 15mg of the drug were administered throughout the study. A total of 249 patients with a primary diagnosis of schizophrenia or schizoaffective disorder were randomized. Efficacy measures included the Positive And Negative Syndrome Scale (PANSS) total, PANSS positive, PANSS negative and general psychopathology. Patients were evaluated for efficacy parameters at the end of 2(nd) week and also at the end of study. Unlike the other antipsychotics, aripiprazole was not associated with significant EPS, increase in body weight or increase in QTc interval. Aripiprazole, effective against positive and negative symptoms, is a safe and well-tolerated potential treatment for schizophrenia and schizoaffective disorder.
在 20 世纪 90 年代之前，精神疾病的治疗主要集中在传统药物上，这些药物的耐受性受到锥体外系症状（EPS）的限制。过去十年中，出现了新一代的抗精神病药物。这些药物提供了更好的阴性症状疗效，认知损伤更小，锥体外系综合征风险更低。阿立哌唑是一种新型的非典型抗精神病药物，在许多临床试验中显示出与利培酮和氟哌啶醇相似的疗效。阿立哌唑不会导致明显的催乳素升高，与其他非典型抗精神病药物相比，它与临床显著体重增加的发生率低相关。阿立哌唑是一种用于治疗精神分裂症的研究药物，具有新颖的药理学特征。阿立哌唑为需要抗精神病治疗的患者提供了一种具有有限不良反应的新治疗选择。本研究是一项为期 4 周、开放标签、随机上市后临床研究，使用阿立哌唑作为研究药物。在整个研究过程中，药物的固定剂量为 15mg。共有 249 名患有精神分裂症或分裂情感障碍的患者被随机分组。疗效评估指标包括阳性和阴性症状量表（PANSS）总分、PANSS 阳性评分、PANSS 阴性评分和一般精神病理学。患者在第 2 周末和研究结束时接受疗效参数评估。与其他抗精神病药物不同，阿立哌唑与明显的 EPS、体重增加或 QTc 间隔增加无关。阿立哌唑有效对抗阳性和阴性症状，是精神分裂症和分裂情感障碍的一种安全且耐受良好的潜在治疗方法。
